drugset / Trial / NCT07398638
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, open-label Phase Ib/II clinical study designed to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of lisatoclax in combination with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Timeline
- Start
- 2026-02-28
- Primary completion
- 2029-02-28
- Completion
- 2031-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | 400 mg | — |
| Subject | APG-2575 | Small molecule | 600 mg | — |
| Subject | Polatuzumab Vedotin | Other / unclassified | — | — |
| Subject | Vincristine | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |